Array BioPharma Inc (ARRY)

ARRY (NASDAQ:Drugs) EQUITY
$11.41
neg -0.11
-0.95%
Today's Range: 11.34 - 11.74 | ARRY Avg Daily Volume: 3,979,500
Last Update: 09/20/17 - 12:47 PM EDT
Volume: 2,045,780
YTD Performance: 31.06%
Open: $11.55
Previous Close: $11.52
52 Week Range: $2.39 - $6.56
Oustanding Shares: 171,766,223
Market Cap: 1,939,240,658
6-Month Chart
TheStreet Ratings Grade for ARRY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 8 8 8
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.22 1.22 1.22 1.22
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -15.68
Price Earnings Comparisons:
ARRY Sector Avg. S&P 500
-15.68 0.00 36.80
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
49.03% 211.35% 206.38%
GROWTH 12 Mo 3 Yr CAGR
Revenue 9.40 2.60 0.52
Net Income 0.00 0.40 0.00
EPS 0.00 0.00 0.00
Earnings for ARRY:
EBITDA -0.10B
Revenue 0.15B
Average Earnings Estimates
Qtr (09/17) Qtr (12/17) FY (06/18) FY (06/19)
Average Estimate $-0.22 $-0.24 $-0.98 $-0.38
Number of Analysts 8 7 9 6
High Estimate $-0.14 $-0.17 $-0.63 $0.45
Low Estimate $-0.31 $-0.32 $-1.33 $-0.86
Prior Year $-0.20 $-0.14 $-0.72 $-0.98
Growth Rate (Year over Year) -8.13% -71.43% -36.27% 61.10%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
I really like how these three charts are shaping up on Array.
Bullish and bearish reversals for this week.
These stocks are showing signs of changing direction.
Bearish
Feb 03, 2017 | 7:52 AM EST
ARRY was downgraded from Overweight to Neutral, JP Morgan said. Valuation call, based on a $10 price target.
Bearish
Jan 30, 2017 | 7:11 AM EST
ARRY was downgraded from Outperform to Market Perform, Leerink Partners said. $11 price target. Stock is up 246% since last June, but t...
The market isn't buying that Trump is bad for business
Such unwarranted fears have depressed the sector, which could bounce back after Nov. 8.
Report of settlement turns the market.
I'm even staying away from the appealing stocks.
Portfolio Manager David Peltier discusses a hot biotech stock with a promising clinical pipeline.

Columnist Conversations

The symmetry is holding up in MCD.  Target 1 is 163.34 if we continue to hold above here!  ...
As far as TSLA is concerned, I still have a higher target above the market at the 409 area.  I stated in ...
The TLT setup discussed in my last commentary is a bust. Key support was violated and it violated the recent l...
BBY is getting smoked this mornings(weak forecast).  The stock is off 8% after opening the session with a...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.